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Outline of the thesis: 
The precise role of B cells and humoral immunity in both Multiple Sclerosis and its 
animal model EAE remains a subject of intense debate.  While intrathecal 
immunoglobulin (Ig) production and Ig-deposition in inflammatory lesions is a 
hallmark of MS, mice deficient in B cells and Igs have been shown to develop severe 
EAE. Paradoxically, mice deficient in FcR! are resistant to EAE-induction. We found 
that the functional expression of FcR! on systemic accessory cells, but not CNS-
resident cells, appears to be vital for the development of CNS-inflammation, 
independent of APC function or antibody (Abs) involvement. While we can clearly 
dismiss B cells as mediators in actively, MOG-peptide induced EAE, we found that 
the injection of auto-Abs directed against MOG drastically worsens disease severity, 
inflammation and demyelination. The action of such Abs is again FcR-independent 
and relies entirely on complement activation, as they have no detrimental effect in 
C1q-/- mice. We conclude that Abs generated during the course of EAE induced by 
active immunization are irrelevant for the pathogenesis of EAE, but that under certain 
conditions Abs are capable of driving demyelination in an FcR!-independent but 
complement-dependent fashion. Anti-myelin Abs are thought to contribute to MS 
pathogenesis in a subpopulation of patients, possibly through crosslinking of Fc!R 
and complement activation, although the relative contribution of these effector 
pathways is unclear and requires further study. The studies described in this thesis 
aimed to further elucidate the relevance of B cells as APCs in EAE pathogenesis. 
The inability of MOG protein to induce EAE in B cell-deficient mice indicate that B 
cells are of key importance for the induction of EAE by a large polypeptide, even 
though our data provide evidence that B cells are neglectable as APCs, for protein 
as well as for peptide Ag. 
 - 20 -  
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Zusammenfassung: 
 Die Krankheitsmechanismen der MS sind größtenteils unverstanden und die 
wichtigsten Erkenntnisgewinne beziehen sich auf die experimentelle Forschung am 
klassischen Tiermodell für die MS, der EAE.  Während sich bei MS die Hinweise 
einer Beteiligung von B-Zellen und Immunglobulinen (Ig) häufen, konnten 
voneinander unabhängige Forschungsgruppen zeigen das B–Zell-defiziente Mäuse 
genauso anfällig sind für die MOG-Peptid vermittelte EAE wie ihre Wildtyp-
Kontrollen. Es konnte aber auch gezeigt werden, dass Myelinprotein-spezifische 
Antikörper in der Lage sind die Demyelinsierung zu verstärken und die 
Effektorfunktionen während der EAE voranzutreiben. Die Möglichkeit das B Zellen 
aufgrund ihrer Fähigkeit Antigene (Ag) zu präsentieren die EAE-Pathogenese 
beeinflussen könnten, wurde mit dieser Arbeit widerlegt.  Nicht zuletzt deshalb, weil 
wir zeigen konnten dass die EAE Resistenz B–Zell-defizienter Mäuse bei 
Immunisierung mit MOG Protein anstelle von kurzkettigem Peptide, keinen Einfluss 
auf die Proliferation krankheitsverursachender T Zellen hat. Im Gegensatz zu all 
diesen Befunden sind Fc-Rezeptor-defiziente Mäuse (FcR!-/-) durchweg resistent 
gegenüber der EAE-Induktion oder zeigen erheblich mildere Verlaufsformen der 
Krankheit. Dies steht im offensichtlichen Widerspruch zu den mit den B-Zell-
defizienten Mäusen gemachten Beobachtungen. Wir fanden heraus, dass die 
beobachtete EAE Resistenz der FcR!-/- Mäusen komplett unabhängig von einer Ig-
Bindung und deren Folgen ist  und das tatsächlich eine alternative Funktion der FcR! 
Kette, auf einem nicht im ZNZ angesiedelten Leukozyten, existiert.  Desweiteren war 
es uns möglich zu zeigen, dass die krankheitsverstärkenden Eigenschaften 
autoreaktiver anti-MOG Antikörper nicht FcR mediert sind, sondern vielmehr deren 
Effektorfunktionen durch das klassische Komplementsystem vermittelt werden.  
 - 22 -  
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1. Multiple Sclerosis  
MS is an inflammatory disease that affects the central nervous system (CNS), 
i.e. the brain and spinal cord, and usually starts between 20 and 40 years of 
age. Clinical signs are heterogeneous, including a wide variety of motor deficits 
such as muscle weakness, tremor and paralysis, often accompanied by sensory 
deficits, such as visual impairment1. The prevalence of MS varies significantly 
depending on the genetic background of the patient2. A considerable number of 
genetic polymorphisms, mostly in genes related to the immune system, have 
been associated with MS susceptibility3. Even in areas with high prevalence, 
MS is more prevalent in Caucasians and only rarely observed in Asians or 
Africans. Moreover, the risk of developing the disease is significantly higher in 
family members of patients with MS4. Environmental factors implicated in MS 
pathogenesis, include geographical differences in exposure to sunlight (vitamin 
D) and infections5. The disease process in MS is characterized by large, sharply 
demarcated areas of demyelination in the CNS, associated with macrophage 
and B cell infiltration, accumulation of perivascular and parenchymal T cells, 
and activated microglia. Tissue damage, including loss of neurons and 
oligodendrocytes (ODCs), astrogliosis and remyelination, accompanies the 
inflammatory changes6.  
 
2. EAE 
Immunological processes contributing to CNS inflammation and demyelination, 
including the role of humoral immunity, are mostly studied in animal model of 
MS, the EAE (experimental autoimmune encephalomyelitis). EAE shares many 
features   with   MS,   such   as   acute,   chronic   and   relapsing   neurological 
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dysfunction, paralysis and ataxia, and strikingly similar histopathological 
changes depending on the model7. EAE can be induced in a number of 
susceptible animals by immunisation with CNS homogenate or purified myelin 
proteins, such as MOG (myelin oligodendrocyte glycoprotein), PLP (proteolipid 
protein) or MBP (myelin basic protein) emulsified in complete Freund`s adjuvant 
(CFA) (active immunisation)8. Generally, immunisation with myelin antigens 
induces a T cell mediated autoimmune response. T cells specific for myelin 
antigens are activated in the periphery, migrate to the CNS, cross the blood 
brain barrier (BBB) and enter the CNS parenchyma. Local re-activation of 
myelin specific T cells results in the activation of microglia and perivascular 
macrophages and the recruitment of peripheral blood immune cells, to the CNS 
parenchyma9. Invading immune cells, such as macrophages, B cells, NK cells, 
granulocytes and CD8+ cells then start a local inflammatory and demyelinating 
response that results in the motor deficits, which are the read-out system for 
clinical EAE. The role of an autoimmune response and the pivotal importance of 
T cells in this model was proven by adoptive transfer experiments, which 
showed that activated CD4+ T cells from a diseased animal can transmit 
disease to naïve animals10. However, the characteristics of EAE in the different 
models, such as disease incidence, day of disease onset, disease severity and 
the extent of CNS inflammation and demyelination may depend on additional 
factors, such as the activation of the humoral immune response6. 
 
3. Humoral Immunity in MS and EAE 
The contribution of the B cells, Abs and complement in EAE is highly variable in 
between  the  different models, and  therefore it is often difficult  to  compare the  
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results obtained in the different studies. This paragraph, will review the studies 
of humoral immunity mainly in EAE but also in MS and interpret the results. 
Furthermore it will address the relevance of Fc!R and complement in Ab-
mediated demyelination. 
 
3.1. B cells and antibodies 
Although B cells are known to be associated with MS lesions, where they can 
potentially contribute to lesion formation by the production of myelin specific 
Abs11-16, information on their physiological and pathological function is still 
sparse. An increased intrathecal production of Immunoglobulins (Igs) in the 
cerebrospinal fluid (CSF) is evident in more than 90% of MS patients17, 18. It was 
found that the increased Ig concentration in CSF of MS patients correlates with 
episodes of MS relapses, and MS patients lacking oligoclonal bands (OCB) are 
considered to develop a more benign disease course19. Generally, the reperoire 
of anti-myelin Abs in the serum is more diverse and less specific for MS than 
those in the CSF. The antigen (Ag) specificity of OCBs in MS patients however 
is largely unknown. It has been reported that OCBs are detected against MBP 
and viral Ags, although generally the IgGs in the OCBs do not represent 
responses against myelin or infectious agents20. It is possible that OCBs in MS 
are directed against Ags that are as yet unknown (i.e. viral Ags or modified self 
Ags). OCBs are not only detected in CSF, but can also be eluted from MS 
lesions21, suggesting that at least part of the OCBs found in the CSF are 
produced at the site of demyelination. In addition, anti-myelin Ab responses 
may vary in different stages of the disease as a result of spreading of B cell 
epitopes, as has been described for T cell epitopes in MS22 and as is repeatedly  
                                                                                                                                Chapter 1 
 - 32 - 
 
described in EAE23. Beside the notion that B cells can contribute to autoimmune 
disease directly, or indirectly via forming immune complexes (ICs)24-26 or as 
regulatory cells by the production of cytokines (IL-10, TGF-!)27, 28. B cells 
however also have the capacity to promote T cell activation29-32, as antigen 
presenting cells (APCs) for priming naïve CD4+33-35 or memory CD4+ T cells36, 
although B cells seems to be limited in their ability to function by acting as 
primary APCs37. Furthermore Ag presentation to T cells by B cells often seems 
to be unfavorable for cellular responses and lowers the amount of Ag available 
for other APCs. 
 
The precise role of B cells and the relevance of anti-myelin Abs in EAE is a 
subject of intense debate27, 28, 38-46. In EAE, no direct correlation between 
neuroantigen-specific Ig titers and disease severity could be demonstrated38. 
EAE studies in mice genetically deficient in B cells (µMT) using peptide of MOG 
and MBP found no requirement for B cells or Abs in disease induction or 
demyelination39-43. On the contrary, B cells are found to exert regulatory effects 
and IL-10 producing B cells are thought to limit the extent of immunity against 
the CNS27, 28. Others however claim that B cells and Abs are, in general or 
under certain conditions, important for the disease process40, 41, 47-51. Transgenic 
expression of a B cell receptor specific for MOG leads to an aggravated form of 
disease after immunization and anti-myelin Abs exacerbate CNS inflammation 
and demyelination in EAE44. Although µMT mice develop EAE following 
immunization with an encephalitogenic MOG peptide (MOG35-55), they were 
found to be resistant to disease induction via immunization with human but not 
rat  recombinant  MOG protein40, 47, 48.  Rat  rMOG  protein,  which  contains the 
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encephalitogenic rodent peptide, induce EAE in the absence of B cells but not 
human rMOG, although human MOG35-55 is encephalitogenic
48. These findings 
indicate that protein-induced EAE is mediated in part by B cells acting as APCs 
and that a single amino acid substitution in human rMOG (position 42), changes 
the mechanism of encephalitogenicity from B cell dependent to independent45-
47. However, this finding was disputed by Fillatreau et al.27. 
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Box 1.1. B cells and Immunoglobulins 
 
B cells originate from lymphoid precursors in the bone marrow and account for 10-15% of blood 
lymphocytes. Their main function are production of immunoglobulins (Ig) and antigen 
presentation to T cells.  Antigen (Ag) specificity of B cells is determined by the B cell receptor 
(BCR) that consists of a membrane bound Ig molecule associated with the Ig"Ig! heterodimer. 
Mature naïve B cells express low levels of low affinity membrane bound IgM molecules. 
Encounter of specific Ag induces B cell activation and differentiation, resulting in secretion of 
low affinity IgM in pentameric form. B cell activation occurs predominantly in the lymph nodes 
(LN), where follicular dendritic cells (FDCs), that have captured Ag in the form of immune 
complexes (ICs) present Ag to B cells. Like T cells, B cells require more than just the presence 
of Ag to become fully activated. The additional activating signal can be provided by CD4
+
 T cells 
or by microbial Ag. 
 
T cell-dependent B cell activation. After binding to protein Ag, B cells internalise the BCR-Ag 
complex, process the Ag and present it as a peptide on MHCII molecules. Recognition of the 
MHC-peptide complex by CD4
+ 
T cells results in activation of B cells, but also in enhanced 
activation of the T cells through costimulatory interactions (such as CD40-CD40L), and B7-
CD28). B cells subsequently undergo somatic hypermutation of the IgV genes, resulting in the 
selection of high affinity BCR and production of high affinity antibodies (Abs) (affinity 
maturation). In addition, rearrangement of the heavy chain results in the selection of another 
IgFc tail, changing the Abs isotype from IgM to IgG, IgA or IgE (isotype switching), alters 
antibody effector function without altering Ag specificity. Differentiation and affinity maturation 
results in the generation of memory B cells that express a high affinity BCR, produce low levels 
of Abs and can undergo new cycles of activation and differentiation upon reencounter with the 
Ag. Alternatively, B cells may develop into end-differentiated plasma cells that have lost all 
surface Igs and continuously secrete high levels of Abs. 
 
T cell-independent B cell activation. High doses of microbial Ag activate B cells regardless of Ag 
specificity (polyclonal activation), whereas lower doses only activate Ag specific B cells although 
without T cell help. The alternative route of T cell-independent B cell activation is by repeating 
linear Ag that simultaneously crosslink multiple Ag specific BCR. Isotype switching or 
development of memory B cells does not occur after T cell independent B cell activation. 
 
Antibodies and Immune complexes. Immunoglobulins (Igs) bind Ag in their native form, 
including conformational epitopes. This is in contrast to T cells, which recognize peptide Ags 
(linear epitopes) in the context of MHC molecules. Binding of Abs to soluble Ag results in the 
formation of immune complexes (IC), whereas binding to particulate Ag, expressed on the 
surface of microorganisms or cells, results in opsonisation of the particle, efficiently targeting the 
particles removal by mononuclear phagocytes. The effector functions of Igs depend on the Ig 
isotype. Binding of pentameric IgM to Ag results in efficient complement fixation, facilitating 
capture and removal of Ag by phagocytes. IgG-containing IC are capable of complement 
fixation and crosslinking of leukocyte Fc! receptors (Fc!R), including a variety of effector 
function (including Fc!R mediated phagocytosis, Ag presentation and Abs dependent 
cytotoxicity). IgA Abs are secreted as dimers in the lumina of mucosal surfaces and mainly act 
as neutralising Abs, in blood IgA occurs in monomers with unknown function. IgE Abs acts as 
Ag receptors on mast cells by Fc-mediated binding to mast cell Fc# receptors that are capable 
of inducing potent inflammatory reactions after cross-linking by Ag
52
. 
 
B cells as antigen presenting cells (APC). Although B cells are poor activators of naïve T cells, 
memory B cells are potential APCs that were shown to be important for propagation of T cell 
responses in several autoimmune disease, including classical T cell mediated diseases
53
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3.2. Fc-receptors 
Whereas the role of Igs in MS and EAE remains enigmatic, the function of Ig-
binding molecules (Fc-receptors) in neuroinflammation is equally controversial.             
Several studies characterized the presence and expression Fc! receptors 
(Fc!R) in MS. All three subclasses of Fc!Rs (Fc!RI, Fc!RII and Fc!RIII), are 
constituively expressed by ramified microglia and perivascular macrophages in 
the CNS54. Fc!R expression is enhanced on lipid-laden macrophages in active 
MS lesions55. Prineas and Graham56, showed capping of phagocytic 
macrophages with IgG in MS lesions, suggestive of Ab mediated phagocytosis. 
However, colocalisation of Fc!R with IgG has not been described in MS lesions, 
the binding of auto-Abs to myelin particles may trigger the inflammatory process 
by activation of Fc!R on microglia and macrophages in the CNS57-59. The 
capacity of Fc!R to contribute to myelin phagocytosis was demonstrated in 
vitro, where myelin specific Abs enhanced myelin phagocytosis in the absence 
of active complement60. In addition, cultured microglia produced inflammatory 
chemokines upon Fc!R crosslinking, supporting a pathogenic role for IgG-Fc!R 
interactions in the CNS61. Genetic differences between FcRs have been 
described in patients with autoimmune diseases62-66. Myhr et al.62 reported an 
association between Fc!R genotypes and MS disease course in 136 Norwegian 
MS patients. Nevertheless because Fc!R genes are in close proximity to each 
other on human chormosome 1, it remains possible that they are in linkage 
disequilibrium with each other, so correlations with one Fc!R genotype might in 
fact implicate other Fc!R genes in disease susceptibility. The balance between 
activatory and inhibitory Fc!R was shown to be very important in Ab-mediated 
autoimmune disease. FcR! chain knockout mice (FcR!-/-), lacking the activatory 
Fc!RI and Fc!RIII67, were protected from collagen- and immune complex-
induced arthritis68, glomerulonephritis69, and vaculitis70. In contrast, mice 
deficient in the inhibitory Fc!RII developed spontaneous glomerulonephritis71 
and were more sensitive to collagen-induced arthritis72.  
 
It is also well documented that the FcR !-chain (FcR!) is important in the 
development of EAE73. FcR!-/- mice are EAE resistant74-76, even though they 
develope  comparable  levels  of MOG-specific Abs74, 75. By contrast, the lack of  
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inhibitory Fc!RIIb enhanced susceptibility to MOG-induced EAE and increased 
the extent of demyelination75. This led to the conclusion that interactions 
between anti-myelin Abs and Fc!R are important for the induction of EAE and 
that the resistance of FcR!-/- mice to EAE is due to the inefficient antigen 
processing or presentation of myelin proteins during the induction of secondary 
immune response locally in the CNS. FcR! is not only critical for FcR-mediated 
signaling, but this ITAM motif-containing !-chain is further involved in the signal 
transduction of several other FcR-unrelated receptor complexes on different cell 
types. These include NKR-P1 on NK-, NK T- and dendritic-cells (DCs); Pir-A on 
DCs, macrophages, B cells and platelets. Furthermore FcR! is closely related 
to the "-chain of the T cell antigen receptor (TCR)/CD3 complex and in fact 
FcR!-" heterodimers and FcR!-FcR! homodimers can participate in TCR 
formation and function77-84. Indeed, Szalai et al. have even suggested that FcR! 
signaling on !/# T cells could explain the resistance of FcR!-/- mice to EAE77. 
They implied that expression of FcR! by !# T cells, probably in conjunction with 
the T cell receptor/CD3 complex, is potentially required for full development of 
EAE. 
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Box 1.2. Fc receptors (FcR)  
 
Fc-receptors (FcR) function as a bridge between humoral and cellular immunity by orchestrating 
the interaction of Abs with effector cells. Two general groups of FcR can be distinguished: those 
expressed by leukocytes that are specific for each of the five immunoglbulins classes (IgA, IgE, 
IgG, IgM and IgD) and that trigger effector functions, and those that mediate transport of Igs 
across epithelial or endothelial surfaces (poly-Ig receptor and FcRn)
85
.  
 
Fc! receptors (Fc!R), play a critical role in immunity by linking IgG Ab mediated responses with 
cellular effector and regulatory functions of the immune system
86
.  
 
Human Fc!R consists of three Fc!R subclasses, Fc!RI (CD64), Fc!RII (CD32) and Fc!RIII 
(CD16), all of which are encoded by genes on chromosome 1. Fc!R belongs to the Ig 
superfamily and contain two (Fc!RII and III) or three (Fc!RI) Ig-like extracellular domains, one 
transmembrane domain and cytoplasmic domains of variable length
65
. For optimal surface 
expression and signal transduction Fc!RI depends on accociation with a dimer of the FcR! 
chain that contains an intracellular immunoreceptor tyrosine-based activation motif (ITAM). In 
the absence of the FcR! chain, surface expression of Fc!RI is severely reduced and most 
effector functions are severely impaired. Human leukocytes express two functional Fc!RII, 
Fc!RIIa and Fc!RIIb. Fc!RIIa is an activating receptor that contains an intracellular ITAM, and 
is independent of the FcR! chain for functional expression and signalling. Fc!RIIb is the only 
inhibitory Fc!R found in humans and has an immunoreceptor tyrosine-based inhibitory motif 
(ITIM) in its intracellular domain. Fc!RIIIa is a transmembrane receptor that is dependent on 
association with a signalling molecule for functional expression. Fc!RIIIa primarily associates 
with a dimer of FcR! chains, but association with a dimer of CD3$ chains or a heterodimer of 
the ! and $ chains is also possible
87
. Fc!RIIIb is a glycophosphatidylinositol (GPI) linked 
molecule that lacks a transmembrane domain. Fc!RIIIb is thought to capture IC without inducing 
inflammation
88
. 
 
Murine Fc!R Several differences exist beween the human and murine Fc!R system. Murine 
Fc!RI is encoded on chromosome 3 whereas Fc!RII and Fc!RIII are encoded on chromosome 
1. Murine Fc!RI depends on FcR! chain for signal transduction and surface expression
67
. 
Murine Fc!RIIIa is also fully dependent on a dimer of FcR! chain for surface expression and 
signalling.  
 
 
3.3. Classical complement system 
The complement system is well represented in the CNS. Glia cells and neurons 
express all of the activation and regulatory proteins and the C3a/C5a 
receptors89-92. It has been suggested that the activation of the complement 
system is involved in the pathogenesis of several neurodegenerative disease 
including Alzheimer`s93, 94, Parkinson`s, Huntington`s, Prion diseases95, 96, and 
MS58, 97-103. Enhanced expression of mRNA for C1q and to a lesser extent C3, 
in MS lesions demonstrates that at least part of the complement proteins are 
produced locally in areas of active demyelination104, 105. Gene-microarray 
analysis of active MS lesions also previously showed enhanced mRNA 
expression for C1r76, a protein that forms the C1 complex with C1q and C1s. In 
a  subgroup  of  early  MS   patients,   deposition  of  IgG,  anti-myelin  Abs  and  
                                                                                                                                Chapter 1 
 - 38 - 
 
complement was detected together in active demyelination lesions in situ11, 15, 58, 
106, 107. This suggests that Ab-mediated activation of complement is involved in 
the demyelinating process in a subpopulation of MS patients. 
 
The role of complement activation in EAE has been hotly debated over the past 
years108-110.  Loss of C3 apparently attenuates EAE111 and expression of the 
complement inhibitor sCrry prevents EAE112. On the one hand complement 
activation appears to be crucial in the context of EAE exacerbated by the 
inoculation of demyelinating Abs57, 113-115, and on the other hand, studies109, 110 
could demonstrate that key components of the complement system, such as C3 
and C4, are not involved in MOG35-55 induced EAE pathogenesis challenging 
the notion that complement activation drives demyelination. The capacity of 
anti-myelin Abs to exacerbate clinical signs of EAE is mostly restricted to Abs 
directed against MOG and indeed the Abs that could fix complement most 
efficiently had the highest demyelinating potential113. Previous studies 
demonstrated that complement depletion cannot116, or not completely117, 
prevent acute exacerbation of EAE by anti-MOG Abs implicating other effector 
mechanisms such as ADCC. While these findings are indicative of a role of the 
complement system, they provide by no means conclusive evidence. Our study 
of anti-MOG Ab-exacerbated EAE in complement deficient mice, definitively 
implicates the complement system as the dominant if not the only effector 
cascade invoked by demyelinating Abs118. 
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Box 1.3. The complement system 
 
The complement system is composed of a large number of serum proteins and membrane-
bound receptors that serve to protect the host from pathogens through innate and adaptive 
immune mechanisms
119, 120
. Activation of the complement system is initiated by binding of 
complement to immune complexes (IC) (classical complement system), pathogens (alternative 
pathway) or modified self-antigens. Binding of the first complement component induces a 
cascade of reactions that results in opsonisation or lysis of pathogens. Complement 
components are also involved in clearance of apoptotic cells, inflammation and tissues 
destruction.  
 
The classical pathway is activated by binding of C1q to IC or apoptotic cells
121
. C1q is the first 
subcomponent of the C1 complex and initiates the complement cascade`s classical pathway by 
binding the FcR-protion of IgG engaged in ICs
122
. In its inactive state, C1q forms a complex with 
C1r and C1s. This complex disintegrates upon binding of C1q to IC, releasing C1r and C1s from 
the complex, thereby exposing an enzymatic site on C1r that cleaves C1s to become an active 
protease. C1s then initiates a cascade of reactions, leading to cleavage of complement C4, C2, 
C3 and C5. After cleavage one part of the protein is released as an inflammatory mediator (C2a, 
C4a, C3a and C5a) and the other part either acts as a new enzyme (C2b) to cleave other 
complement components or binds to the pathogenic or apoptotic surface as an opsonin (C4b, 
C3b). Binding of C5b to C3b on the opsonised surface initiates the final pathway of complement 
that is shared by all three pathways. C5b forms complexes with C6, C7 and C8, which insert 
itself into the membrane. C9 molecules then bind to this complex and polymerise, forming a 
pore in the pathogenic membrane – the membrane attack complex (MAC) – that contributes to 
lysis of the pathogens
120
. 
 
The Mannan-binding lectin (MBL) pathway is initiated by binding of mannose binding lectin to  
microbial  pathogens
123
,  ficolins
124
, and IgA-containing immune complexes
125
, followed  by 
cleaving  of  C4  and  C2  and further activation of the complement cascade similarly to the 
classical pathway. 
 
The  alternative  pathway  is  activated  by direct binding of C3 to pathogens, followed by 
activation of series of proteins (factor B, factor  D  and  factor  P)  that  amplify  the response by 
cleaving more C3 into C3a and C3b. C5b then binds  to C3b, initiating  the final pathway of 
complement.  
 
Complement receptors.  After complement opsonisation, pathogens or apoptotic cells can 
induce leukocyte activation or phagocytosis mediated by complement receptor (CR)
126
. Mouse 
CR1 (CD35) and CR2 (CD21) are alternatively spliced products of the same Cr2 gene, while in 
humans these proteins are derived from two distinct but closely linked genes on chromosome 
1
127
. CD35/CD21 is expressed primarily by mature B cells and follicular dendritic cells (FDC) 
where it associates with CD19, a response regulator of transmembrane signals during B cell 
activation
128
. CD35 binds surface-bound C1q, C3b, C4b, MBL and the inactivated form of C3b 
(iC3b). CD35 cannot directly mediate phagocytosis, but the uptake of complement-opsonised 
targets under inflammatory conditions is greatly enhanced after CD35 crosslinking. B cells and 
FDCs recognize surface-bound C3d through CD21, resulting in a sustained B cell activation
129, 
130
. CR3 (CD11b) and CR4 (CD11c) are expressed predominantly on myeloid cells and mediate 
phagocytosis of C3b opsonised targets. 
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1. B cell-deficient  JH
-/- mice are fully susceptible to MOG35-55–induced EAE 
 
µMT mice, in which the gene for the membrane µ-heavy chain is disrupted, are 
frequently used as a model for B cell-deficiency1 and are widely used in EAE-
studies2-10. Nonetheless, µMT mice have been shown to produce IgA and IgA-
producing B cells casting doubt upon the applicability of this B-cell deficiency 
model11. On the other hand, JH
-/- mice, which have a targeted deletion of all JH gene 
segments, completely lack Ig expression and mature B cells12. To determine the 
involvement of B cells in the induction of EAE, we immunized JH
-/- mice with MOG35-55 
peptide emulsified in complete Freund’s adjuvant (CFA) and 7dpi lymphocytes were 
challenged with either cognate Ag (Figure 1) or with mitogen (data not shown). We 
found that B cell-deficiency does not affect cognate antigen-driven lymphocyte 
proliferation (Figure 1A) or effector cytokine production (e.g. IFN!/IL-17) (Figure 1B). 
Furthermore these data demonstrate that T cells in the JH
-/- mice are functionally 
intact and can be activated through conventional activation pathways. Furthermore 
the JH
-/- mice developed a similar chronic and sustained disease (Figure 2A, Table 1). 
Disease onset was equivalent in wt control BL/6 and B cell deficient mice. Patterns of 
inflammation and demyelination, as well as the total size of structural damage in the 
spinal cords (Figure 2B), revealed only minor differences between JH
-/- and wt control 
mice. Both displayed an influx of CD3+ T cells and Mac-3+ monocytes/macrophages 
into the CNS, which relatively reflected the severity of clinical disease. Wt mice 
display a significant portion of invading B cells, while the also susceptible B cell-
deficient mice expectedly did not, implying that B cell invasion seen in wt mice is 
either an epiphenomenon or that invading B cells serve a regulatory function as 
suggested previously2, 3, 13, 14.  
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Figure 1 !  B cells are not required for Ag-proliferation or effector cytokine production 
Proliferation (A) and cytokine secretion (B) of lymphocytes from wt and JH
-/- 
mice immunized with MOG35-55. (A) wt and JH
-/- 
mice 
were immunized with MOG35-55 emsulfied in CFA or CFA alone. Regional draining LNs were removed 7dpi and a single-cell 
suspension was restimulated with MOG35-55 (50µg/ml) in 96 well plates. T cell proliferation was determined by 
3
[H]-thymidine 
incorporation in triplicate wells for 48 hours. Representative data from at least 2 experiments are presented as mean counts per 
minute (cpm) of triplicate cultures. Open bars represent control unstimulated cultures; filled bars are Ag stimulated cultures. (B) 
ELISPOT analyses for IFN-! and IL-17 production from draining LN derived lymphocytes. Lymphocytes were prepared from wt 
and JH
-/- 
mice immunized with MOG35-55 7dpi.  IFN-! and IL-17 secretion was elicited with restimulation with MOG35-55 (50µg/ml) 
(filled bars) or medium (open bars) for 24 hours. Data shown represent the mean of two individual experiments ± SEM. 
 
 
 
 
Table 1 !  Clinical parameters of MOG35-55-
induced EAE in wt and B cell deficient  JH
-/-
 
mice  
Data are cumulated and averaged from four 
separate experiments. 
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Figure 2 !  B cell deficient JH-/- mice are susceptible to MOG35-55  induced EAE 
EAE was induced in (A) JH
-/-
 (squares) and wt (circles) mice by immunization with MOG35-55 in CFA and the mice were scored 
daily for clinical symptoms. The figure is a representative of at least four individual experiments (total n"6/group). Statistical 
significance was determined using Student's t-test. B cell deficient JH
-/-
 mice show CNS inflammation and demyelination after 
immunization with MOG peptide. (B) Paraffin-embedded spinal cord lateral column white matter of lumbar sections were 
prepared from perfused wt and JH
-/-
 , animals at day 24 after induction of EAE with MOG35-55. Hematoxylin and eosin (H&E) 
stains infiltrated cells, whereas luxol fast blue (LFB) shows myelin. Immunocytchemistry for CD3
+
, MAC-3
+
 and B220
+
 subsets, 
shows infiltrating T cells, macrophages and B cells respectively.  
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2. B cells are critical for the induction of EAE by mouse and human MOG 
protein 
 
Recent studies have indicated a role for different populations of APCs in the priming 
of naïve T cells in response to peptide vs. protein Ag and in this regard a crucial 
considerate to the origin of the protein Ag15, 16. While B cell-deficient mice developed 
EAE upon immunization with both human and rat MOG-peptide, recombinant full 
length human but not rat protein failed to induce EAE in µMT mice. This suggests 
that B cells are required to process and present Ag for proper T cell priming by 
different origin dependent mechanisms6, 16, 17. The recombinant MOG protein (rMOG) 
represents the mouse 121- respectively human 125-amino acids extracellular domain 
of MOG and contains the encephalitogenic MOG35-55 peptide (Figure 3)
18.  
 
Figure 3 !  Verification of the 
purified human and mouse rMOG 
by Western Blot analysis                                     
The extracellular human rMOG1-125 
and mouse rMOG1-121 protein were 
expressed in Escherichia coli, purified 
by Ni-chelate column and pooled 
protein containing fractions were 
dialyzed into acetate buffer and 
concentrated. Protein purity was 
assessed by (A) Ponceau-staining 
and (B) SDS-PAGE using an anti-
MOG antibody (8-18C5) and a 
secondary goat-anti mouse-HRP 
antibody. 
 
 
To assess whether B cells serve as APCs in the initiation of a T cell response to 
encephalitogenic protein antigens we immunized JH
-/- and wt mice with either a 
recombinant mouse MOG1-121 protein (rMOG1-121) (Figure 4, Table 2) or recombinant 
human  MOG1-125  (rMOG1-125)   (Figure 4)  and  followed  the  development   of  EAE.  
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Table 2 !  Clinical parameters of 
mouse rMOG1-121-induced EAE in 
wt and B cell deficient  JH
-/-
 mice  
Data are cumulated and averaged 
from three separate experiments. 
 
 
 
In contrast to the findings by Oliver et al.16, 17, diseases induced with mouse MOG1-121 
protein was significantly milder in JH
-/- compared to wt animals (Figure 4, Table 2) 
and we found JH
-/- mice to be fully resistance to the induction and progression of EAE 
after immunization with human MOG1-125 protein (Figure 4). These results indicate 
that B cells are of key importance for the induction of EAE by a large polypeptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 !  B cell deficient mice are resistant or developed milder diseases to 
protein-induced EAE 
wt (circles) and  JH
-/-
 (squares) mice were immunized with mouse rMOG1-121 (open 
symbols) or human rMOG1-125 (filled symbols). Mice were examined daily for clinical 
disease. The figures are representative of at least two separate experiments (total 
n"6) and were analyzed for statistical significance using a Student's t-test (*<0,05, 
#<0,01). The table contains cumulated and averaged data from two separate 
experiments including the graph shown above.  
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3. MOG transgenic T cells proliferate in response to rMOG protein in JH
-/- 
mice 
 
One explanation for the inability of MOG protein to induce EAE in B cell-deficient 
mice is that B cells play a role in the processing and presentation of the intact 
protein. It was previously demonstrated that mice lacking B cells (µMT) are impaired 
in their priming of T cells to protein but not peptide Ag15.  Therefore we analyzed the 
capacity of JH
-/- mice to develop a protein or a peptide Ag-driven immune response. 
We adoptively transferred CFSE (carboxy fluorescein diacetate succinimide ester)-
labeled TcR-transgenic (2D2) T cells, specific for MOG35-55 peptide
19 into either wt or 
JH
-/- mice. These cells had been labeled with CFSE, a fluorescent dye, which is 
passively incorporated into cells. Upon cell division the dye is divided equally 
between the daughter cells. Hence, every division reduces the dye intensity to the 
half. They were subsequently immunized with their cognate peptide (MOG35-55), 
mouse rMOG1-121 or human rMOG1-125 protein emsulfied in CFA. After 4 days, 
proliferation of TcR Tg-T cells in lymph nodes (Figure 5) and spleen (data not shown) 
was determined by flow cytometry. As shown in Figure 5, CD4+ TcR Tg-T cells 
proliferated to a similar extent in all JH
-/- groups in  comparison to their wt control 
groups  in vivo after immunization. No responses were observed in only CFA 
immunized mice. This data, therefore provide evidence in support of a preferential 
uptake and presentation of mouse in comparison to human rMOG in vivo, although 
all groups showed less proliferation by immunization with protein than with cognate 
peptide. These data indicate that B cell-deficient mice are capable of processing and 
presenting the rMOG protein. 
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Figure 5 !  B cells are not required  
to process and present MOG 
proteins 
To assess the expansion of MOG-
specific transgenic (2D2 Tg) T cells in 
the context of JH
-/-
 or wt host, 15x10
6 
lymphocytes from naïve 2D2 TCR 
transgenic mice were labeled with 10 
µM CFSE and injected i.v. Recipients 
were subsequently immunized s.c. 
with MOG35-55, mouseMOG1-121 or 
humanMOG1-125 emulsified in CFA or 
CFA alone (grey). FACS analysis 
draining LNs was performed 4dpi. 
Gating on transgenic V#3.2
+
 cells 
permits to specifically follow the 
proliferation of the adoptively 
transferred T cells. Shown is a 
representative of two individual 
experiments (n " 2). 
 
 
 
 
 
 
 
 
4. Resistance of B cell-/- mice to MOG protein induced EAE does not 
depend on humoral anti-MOG response 
 
Another possible explanation for the differential B cell dependence of MOG protein 
and MOG peptide is that immunization with encephalitogenic MOG35-55 peptide is a 
consequence of T cell epitope immunodominance20, 21. Furthermore the recognition 
of structural eptiopes of MOG could not only influence the binding of Abs in vivo but 
also result  in  different  effector  mechanisms  for  Abs  pathogenicity22. To test  if the  
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presence of conformational specific Abs contributes potentially to the development of 
EAE we first analyzed the levels of total Ig anti-MOG auto-Abs. Sera from MOG35-55, 
MOG1-121 or Myelin immunized mice (Figure 6) were tested 12 dpi by using MOG35-55 
coated (Figure 6A) or MOG1-121 coated (Figure 6B) ELISA plates. Surprisingly the 
polyclonal Abs present in serum of Myelin or MOG1-121 immunized wt mice do not 
recognize the linear Ag corresponding the short 35-55 peptide, which is also a part of 
MOG1-121 (Figure 6A). In contrast, in animals immunized with MOG35-55, the repertoire 
of MOG reactive Abs was not restricted to linear epitopes (Figure 6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 !  Igs from wt mice immunized with mouse MOG peptide, protein or myelin 
Serum antibody responses following MOG35-55 (200ug/mouse) (squares), MOG1-121 (200ug/mouse) (circles), Myelin (1:1 in CFA) 
(triangles) or CFA alone (diamonds). Anti-MOG35-55 (A) and anti-MOG1-121 specific (B) total Ig were assessed by ELISA using 
serum diluted 1:100, 1:50, 1:25 , 1:12,5 or 1:500, 1:1000, 1:2000, 1:4000 respectively. All sera were pooled from two mice 12 
days post immunization. Values represent mean OD450nm results (± SEM). 
 
The MOG-specific mouse hybridoma 8-18C5 secretes a conformation-dependent 
anti-MOG mAb that can mediate demyelination in vivo in animals with EAE20, 23, 24. 
The MOG-specific Ab response is complex and recognizes both linear and 
conformation-dependent epitopes. The demyelinating component of this response is 
directed to conformation-dependent epitopes present on the extracellular Ig-like 
domain of the protein, whereas  Abs recognizing linear  MOG peptides are unable to  
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bind to the native protein and are unable to initiate demyelination in vivo20, 23. To 
investigate whether the role of anti-MOG protein Ab is in the priming of 
encephalitogenic T cells, or if these conformational anti-MOG Abs are able in 
trafficking of encephalitogenic T cells into the CNS, JH
-/- mice previously immunized 
with MOG35-55 peptide or MOG1-121 protein were treated with the monoclonal anti-
MOG antibody (mAb) (8-18C5) (Figure 7). We observed that the systemic application 
of the anti-MOG antibody starting at the time of immunization increased clinical signs 
of EAE in both MOG35-55 peptide immunized wt and JH
-/- mice. We also noticed that 
the injection of the anti-MOG Abs did not lead to disease exacerbation in MOG1-121 
protein immunized JH
-/- compared to wt mice (Figure 7).   
 
Figure 7 !  EAE resistance of 
JH
-/- 
mice is independent of a 
monoclonal demyelinating 
Abs 
wt and JH
-/-
 mice were 
immunized with MOG35-55 or 
MOG1-121 in CFA and at days -
1, 3, 5 and 9 of immunization 
animals were given 150µg of 
either #-MOG mAb (filled 
symbols) or equal volume of 
PBS (open symbols) by i.v. 
injection into the tail vein. Mice 
were examined daily for clinical 
disease. 
 
 
 
 
The germinal centres (GC) are the  anatomical site where Ag activated B cells rapidly 
expand and differentiate into either plasma or memory B cells. GCs comprise of 
networks of follicular dendritic cells (FDCs), which play a vital role in the generation 
of a high affinity Ab-response through somatic hypermutation and isotype switching25. 
To  dissect the  relative  contributions  of  high affinity  autoreactive  Abs in  EAE, we  
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treated wt mice with Lymphotoxin-beta-receptor (LT"R)-Fc fusion protein, which has 
been shown to disrupt the formation of tertiary lymphoid tissues26, 27 and assessed 
them for the development of EAE. The LT"R-Fc treated mice, although showed a 
similar disease onset, nevertheless they developed a more severe monophasic EAE 
compared to the human IgG treated control mice (Figure 8A Table 3). In addition, we 
analyzed the level of anti-MOG auto-Abs, in the sera from the LT"R-Fc treated and 
the control mice, by ELISA using MOG35-55 (Figure 8B). As expected, the LT"R-Fc 
treated mice weren`t able to generate high affinity IgGs against MOG but interstingly 
it seemed so that they try to compensate this inability by an increased secretion of 
anti MOG IgM. Taken together, our data clearly demonstrate that B cell activation 
and the generation of high-affinity Abs is not obligatory for EAE development and 
progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 !  The lack of polyclonal anti-MOG 
IgGs has no effect on disease susceptibility 
(A) EAE was induced by s.c. immunization with 
MOG33-55 in LT$R-Fc treated (filled circles) and 
untreated (closed circles) wt mice. Results are 
representative of 2 independent experiments (n " 
5 mice/group). (B) Anti-MOG IgM and IgG Ab 
ELISA from sera of diseased LT$R-Fc treated 
(filled circles), untreated wt (open circles) and 
unimmunized mice (square) (19dpi). Shown is the 
average of 4 mice per group ± SEM. The table 
contains cumulated and averaged data from two 
separate experiments including the graph shown 
aside. 
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1.  Deficiency in FcR! delays onset and decreases severity of EAE, 
independent of Ab binding 
 
It is well documented that the FcR-associated signaling subunit, termed the common 
!-chain (FcR!) is important in the development of EAE as FcR!-/- mice are EAE 
resistant1-3, even though they developed comparable levels of MOG-specific Abs1, 2. 
To assess whether this EAE-resistance is due to the absence of FcR bearing cells to 
cause demyelination of Ab-coated myelin structures, we initially immunized FcR!-/- 
and wt mice (both on the C57BL/6 background) with MOG35-55 in CFA and evaluated 
clinical disease development. Consistent with the findings by Lock et al. in BL/6-
129PF2 strain3, we found that while wt mice developed progressive paralysis, FcR!-/- 
mice were relatively resistant to EAE and developed a significantly (p<0.01) milder 
disease with delayed onset (Figure 1A, Table 1).  
 
The relative EAE resistance of FcR!-/- mice is in clear conflict with the finding that 
mice lacking all Abs develop severe EAE4-9, raising the question as to whether the 
FcR!-deficiency functions independent of Abs. To this end, we crossed B cell 
deficient JH
-/- mice with FcR!-/- mice. JH
-/- mice, which in contrast to the widely used 
"Mt mice (targeted deletion of " heavy chain), are completely deficient in mature B 
cells and Igs10, 11. After induction of EAE, we found that similar to FcR!-/- mice, FcR!-/-
/JH
-/- mice displayed a delayed disease onset and decreased severity (Figure 1B, 
Table 2), demonstrating that the EAE-resistance of FcR!-/- mice functions 
independently of B cells and their products. Immunohistochemical analysis revealed 
significantly reduced pathological changes in the FcR!-/- and FcR!-/-/JH
-/- when 
compared  to  wt  mice.  The FcR!-/-/JH
-/-  mice developed  only mild demyelination as  
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assessed by Luxol-fast blue staining (LFB) and a substantial decrease in cellular 
infiltration (H&E) when compared to wt mice (Figure 11).  
 
In addition, we analyzed the levels of MOG auto-antibodies and antibody responses 
to keyhole limpet hemocyanin immunization (KLH) by ELISA. Sera from both the 
FcR!-/- and the wt mice immunized with either MOG35-55 (Figure 1C) or rMOG1-121 
(Figure 1D) had comparable levels of total Igs, IgG and IgM antibodies. This was also 
the case for KLH as a representative protein antigen (Figure 1E), demonstrating that 
Abs against myelin raised after immunization do not contribute significantly to the 
development of EAE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
 - 73 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 !  The loss of FcR! attenuates EAE development independent of B cell function. 
EAE was induced in (A) FcR!
-/-
 (triangles) and wt (circles) or (B) JH
-/-
/FcR!
-/-
 (squares) and wt (circles) mice by immunization with 
MOG35-55 in CFA and the mice were scored daily for clinical symptoms. The figure is a representative of at least three individual 
experiments (total n#6/group). Statistical significance was determined using Student's t-test (*<0,05, #<0,01). Panels (C-E) 
display the relative analysis of antibody responses from immunized FcR!
-/- 
(triangles), JH
-/-
/FcR!
-/-
 (squares) and wt controls 
(circles). Serum antibody responses following (C) MOG35-55 (200ug/mouse), (D) rMOG1-121 (200ug/mouse) and (E) KLH 
(200ug/mouse) (emsulfied 1:1 in CFA) on day 0, 7, 13 and 19 post immunization (dpi). MOG- and KLH-specific total Ig, IgG and 
IgM levels were assessed by ELISA using serum diluted 1:1000. For 19 dpi sera were titrated 1:500, 1:1000, 1:5000 and 
1:10000. Values represent mean OD450nm results (± SEM) from 4 mice of two different experiments. 
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2. Peripheral leukocytes but not CNS resident cells are required for FcR!-
mediated disease development 
 
CNS-resident microglia are widely held to be central to the development of CNS 
lesions12-16 and their expression of Fc!Rs (Fc!RI, Fc!RII and Fc!RIII) is thought to 
mediate Ab-induced tissue destruction15, 17. The use of BM chimeric mice allows to 
selectively manipulate the genotype of the peripheral haematopoietic immune system 
while sparing host-derived CNS resident cells such as CNS parenchymal microglia, 
astroglia  and  macrophages,  which  are   not   significantly   repopulated   after   BM  
reconstitution13, 18. In contrast to the CNS parenchyma, the genotype of the systemic 
immune compartment and that of perivascular cells can be exchanged with that of 
donor-derived haematopoietic cells13, 14, 19.  
 
To determine the role and function of FcRs expressed by CNS-resident cells, we 
generated a series of BM chimeric mice and induced EAE via active immunization 
with MOG35-55. The absence of FcR! from the radio-resistant (microglia) 
compartment (wt ! FcR!-/-) did not alter the disease course when compared to 
control mice (wt ! wt) (Figure 2A), whereas the deletion of FcR! from the systemic 
immune compartment (FcR!-/- ! wt) resulted in reduced clinical disease (Figure 2B). 
We conclude that FcR! expression by CNS resident cells does not influence the 
course of clinical disease or histopathological changes (data not shown) associated 
with CNS inflammation. Considering the potential direct involvement of FcR! 
signaling in lymphocyte activation20-23, we wanted to assess whether lymphocyte 
function in vivo is directly affected by the loss of FcR! or whether accessory cells 
require  FcR!  for  the  development  of  autoimmunity.  In  order to  narrow  down the  
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FcR!-bearing cell influencing EAE, we constructed mixed BM-chimeras in which the 
FcR!-lesion is restricted to either lymphocytes or to all other leukocytes. To restrict 
genetic deficiency to lymphocytes only, the BM inoculum consisted of 25% RAG1-/- 
BM cells supplemented with 75% BM cells from FcR!-/- mice. Control groups received 
either 100% wt, 100% RAG1-/- or 100% FcR!-/- BM cells. As expected the groups 
reconstituted with 100% RAG1-/- or 100% FcR!-/- were resistant or developed mild 
EAE, respectively (Figure 2B). Mice bearing FcR!-/- lymphocytes but carrying normal 
accessory leukocytes (FcR!-/- + RAG-/-  ! wt) were fully susceptible to EAE and 
indistinguishable from the wt ! wt control group (Figure 2B). Taken together, our 
data demonstrate that FcR! is vital for the development of EAE and it must exert its 
primary effect through accessory cells such as mono- and polymorphonucleated 
phagocytes, dendritic cells (DCs) or natural killer cells (NK cells) but not through 
lymphocytes directly.  
 
 
 
 
 
 
 
 
 
Figure 2 !  FcR!-bearing accessory cells restore EAE susceptibility in BM chimeras. 
(A) BM chimeric mice in which the FcR! deficiency was restricted to CNS-resident cells were generated by transferring 2x10
7 
wt-BM cells into lethally irradiated FcR!
-/-
 (wt " FcR!-/-, open circles) and wt mice (wt " wt, open squares) as a control group. 
(B) Irradiated wt mice were reconstituted with BM cells from RAG1
-/-
 mice (RAG
-/-
 " wt, open triangles), FcR!-/- deficient mice 
(FcR!
-/-
 " wt, filled circles), wt mice (wt " wt, open circles) and a 1:4 mixture of FcR!-/- and RAG1-/- BM cells (FcR!-/- + RAG-/- 
" wt, open diamonds). 8 weeks later, reconstituted BM chimeras (# 6/group) were actively immunized with MOG35-55 in CFA 
and clinical disease development was assessed daily. The table corresponds to the graph shown above. The figure is 
representative of at least two separate experiments (total n# 10). Statistical significance was determined using Student's t-test 
(*<0,05, #<0,01). 
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To determine whether loss of FcR! lesions the capacity of APCs to drive the 
expansion of encephalitogenic T cells, FcR!-/- and wt mice were immunized with 
MOG and 7dpi lymphocytes were challenged with either cognate Ag or with mitogen. 
Interestingly, we found that FcR!-deficiency does not affect cognate antigen-driven 
lymphocyte proliferation (Figure 3A) or cytokine production (e.g. IFN!/IL-2) (Figure 
3B). To corroborate the capacity of FcR!-/- mice to develop a protein/peptide Ag-
driven immune response we adoptively transferred CFSE-labeled TcR-transgenic 
(2D2) T cells, specific for MOG35-55-peptide
24  into either wt or FcR!-/- mice. They 
were subsequently immunized with their cognate peptide (MOG35-55) or MOG1-121 
protein emulsified in CFA. After 4 days, proliferation of TcR Tg-T cells in spleen and 
LNs was determined by flow cytometry. As shown in Figure 3C, all groups displayed 
similar proliferation in vivo after antigen challenge. 
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Figure 3 !  Encephalitogenicity 
but not Ag-proliferation and 
cytokine production are 
dependent on FcR!. 
(A) wt (black) and FcR!
-/-
 (white) 
mice were immunized with MOG35-
55 emsulfied in CFA. Regional 
draining LNs and spleens were 
removed 7dpi and a single-cell 
suspension was restimulated with 
MOG35-55 (50µg/ml), rMOG1-121 
(50µg/ml) or ConA (5µg/ml) in 96 
well plates. T cell proliferation was 
determined by 
3
[H]-thymidine 
incorporation in triplicate wells for 
48 hours. Representative data from 
at least 3 experiments are 
presented as mean counts per 
minute (cpm) of triplicate cultures. 
(B) Lymphocytes were prepared 
from wt (filled circles) and FcR!
-/-
 
(open squares) mice immunized 
with MOG35-55 7dpi.  IFN-! and IL-2 
secretion was elicited with different 
doses of MOG35-55 for 24 hours and 
measured by 
3
[H]-thymidine 
incorporation and ELISA. Data 
shown represent the mean of two 
individual experiments ± SEM. (C) 
To assess the expansion of MOG-
specific transgenic (2D2 Tg) T cells 
in the context of FcR!
-/-
 or wt host, 
25x10
6 
lymphocytes from naïve 
2D2 TCR transgenic mice were 
labeled with 10 µM CFSE and 
injected i.v. Recipients were 
subsequently immunized s.c. with 
MOG35-55, MOG1-121 emulsified in 
CFA or CFA alone. FACS analysis 
of spleen and draining LNs was 
performed 4dpi. Gating on 
transgenic V$3.2
+
 cells permits to 
specifically follow the proliferation 
of the adoptively transferred T cells. 
Shown is a representative of two 
individual experiments (n # 2). 
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3. Loss of FcR! diminishes inflammation during the effector phase of EAE 
 
A possible explanation for the observed function of FcR! on accessory cells is that 
FcR! signaling is important for the capacity of APCs to properly prime and polarize 
naïve T cells towards an effector phenotype. To asses the response of wt and FcR!-/- 
mice to mitogen stimulation and to investigate functionality of the innate immune 
response in FcR!-/- mice, we stimulated lymphocytes obtained from naïve wt or  
FcR!-/- mice in vitro with either concavilin A (ConA) or lipopolysaccharide (LPS) and 
measured proliferation (Figure 4A)  as well as the secretion of IFN-! and IL-2 (Figure 
4B). We did not observe any significant differences between the responses of wt or 
FcR!-/- mice (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 !  Ex vivo proliferative capacity and secretion ability of naive FcR!-/- lymphocytes. 
(A) Measuring of proliferation and (B) ELISA assessing IFN-! and IL-2 secretion by naïve wt and 
naïve FcR!
-/- 
LN and spleen derived cells. They were stimulated for 20 hours with 5µg/ml ConA or 
5µg/ml LPS. 
3
[H]-thymidine was added to the culture 18 hours prior to measuring proliferation in 
counts per minute (CPM). Data shown represent the mean of two individual experiments. 
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We next generated BM-chimeras by transferring 1:1 ratio of FcR! chain deficient BM 
cells (CD45.2) and CD45.1-congenic wt BM cells into lethally irradiated wt recipients. 
Wt-CD45.2 and wt-CD45.1 BM-chimeras were generated as a control. The mice 
were immunized with MOG35-55 and after 7 days splenocytes were removed and 
challenged in vitro with MOG. Neither MOG35-55-peptide nor rMOG1-121-protein 
restimulated FcR! deficient CD4+ cells differ in proliferation from CD4+ cells with 
intact FcR! (Figure 5). 
 
 
Figure 5 !  Antigen specific 
expansion despite FcR!-
chain deficiency. 
The generated wt-Ly5.1 : 
FcR!-Ly5.2 BM-chimeric 
mice, whose immune system 
contain a 1:1 mix of FcR! 
deficient-Ly5.2 (grey line) and 
wt-Ly5.1 cells (black filled) 
were immunized with MOG35-
55 and after 7 days 
splenocytes were challenged 
in vitro with different 
concentrations of either 
MOG35-55 or MOG1-121 (0.5, 5, 
50 µg/m).   
 
 
In a complementary approach to determine the APC capacity of FcR!-/- DCs, we 
exposed immature (Figure 6A) or LPS matured (Figure 6B) bone marrow (BM)-DCs, 
derived from wt or FcR!-/- mice, to p11-peptide and co-cultured them with TcR 
transgenic T cells (SMARTA). After 24 hours, proliferation was measured by using 
3[H] thymidine incorporation. No significant difference in T cell priming between the 
groups was observed regardless of the degree of DC maturation (Figure 6). The 
results suggested that FcR! is not involved in APC maturation or Ag-presentation 
and that priming and expansion of autoreactive T cells is undisturbed.  
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Figure 6 !  Antigen specific expansion despite FcR!-chain deficient BM-DCs. 
(A) Immature bone marrow (BM)-derived DC’s were generated, by addition of GM-CSF, from wt (white) and FcR!
-/- 
(black) mice, (B) matured with 10µg/ml LPS o.N. and subsequently pulsed with 1 µg/ml SMARTA peptide (p11). 
4x105 p11-specific splenic-derived CD4
+
 T cells were obtained from naïve SMARTA-Tg mice and co-cultured with 
the peptide-pulsed (1µg/ml), irradiated (2000 rads) DC’s for 24h when proliferation was assessed by 
3
[H]-thymidine 
incorporation in counts per minute (CPM). Data shown represent the mean of two individual experiments ± SEM. 
 
 
  Chapter 3 
 - 81 - 
 
In order to check the ability of myeloid cells to reach the CNS tissue, we generated 
mixed bone marrow chimeras by transferring CD45 congenic wt and FcR!-/- bone 
marrow into wild-type recipients and evaluated the capacity of myeloid population to 
invade the CNS during disease. We first confirmed that the mice had a 1:1 ratio of wt 
and FcR!-/- hematopoetic cells in peripheral blood and spleens. After EAE induction, 
we found both myeloid populations in the CNS at a ratio of 1:1, indicating that there 
are no difference between the two genotypes of myeloid cells (data not shown). 
 
To assess the role and function of FcR! during the effector phase of EAE we 
determined the susceptibility of FcR!-/- mice to EAE induced by adoptive transfer of a 
population of encephalitogenic lymphocytes. Fully primed and activated 
encephalitogenic wt T cells induced EAE in wt recipients, yet surprisingly they were 
incapable of inducing clinical EAE in FcR!-/- hosts (Figure 7). This finding again 
shows that FcR! signaling is crucial for the actions of the accessory cell 
compartment during the effector phase of the disease. 
 
 
 
Figure 7 !  Deletion of FcR! abrogates 
encephalitogenicity of effector T cells 
in EAE. FcR!
-/-
 (filled circles) and wt 
(open circles) mice received a single 
injection of 30x10
6
 encephalitogenic 
MOG-reactive wt-derived lymphocytes 
(prepared as described above). 3 hours 
later the mice received 200ng PT i.p.. 
Subsequently, the mice were examined 
daily for clinical disease. Data show the 
mean EAE score and the figure is a 
representative of three separate 
experiments (total n=18). Statistical 
significance was determined using 
Student's t-test (*<0,05, #<0,01). 
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4. Exacerbation of EAE after injection of demyelinating anti-MOG mAbs is  
 complement-dependent but not driven by ADCC 
 
After disconnecting the actions of FcR! from the function of anti-MOG Abs generated 
through immunization with MOG, we were pressed to consolidate our findings with 
the fact that $-MOG Abs have been shown to exacerbate EAE25-27. We observed that 
the systemic application of monoclonal anti-MOG antibody (mAb) (8-18C5) starting at 
the time of immunization rapidly increased clinical signs of EAE in both wt and FcR!-/- 
mice, clearly demonstrating that Ab-mediated exacerbation of EAE is independent of 
FcR! (Figure 8). We noticed that this exacerbation of clinical EAE did not affect the 
delayed onset of clinical symptoms characteristic for FcR!-/- mice, again supporting 
the notion that the function of FcR! in EAE is unrelated to Ab binding and FcR! 
signaling may contribute to the preclinical phase of the disease.  The anti-MOG-mAb 
caused strong demyelination and increased cellular infiltration of T cells, 
macrophages and B cells, when compared to mice treated with either isotype control 
Ab or PBS alone (Figure 12).  
 
Numerous studies have documented deposition of complement components in MS 
lesions28-30. Anti-myelin Abs, which are potent complement activators, were also 
recently demonstrated in situ in MS31, 32 and it was shown that injection of anti-MOG 
Abs into animals with acute EAE results in massive activation of complement in 
areas of demyelination27. We therefore investigated the relevance of the immune 
complex-dependent portion of the complement system in the Ab-mediated worsening 
of EAE by injection of $MOG mAbs into MOG immunized C1q-/- mice.  C1q-/- mice 
developed EAE with the same onset and severity as the wt control group after 
immunization with either encephalitogenic MOG35-55 or recombinant mouse and 
human protein (Figure 9) and importantly the injection of the anit-MOG-mAb did not 
lead  to  disease  exacerbation  in  C1q-/-  compared to wt or FcR!-/- mice (Figure 10).  
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Figure 8 !  Demyelinating Abs 
drive the disease process in 
a FcR independent fashion. 
wt (circles) and  FcR!
-/-
 
(squares) mice were immunized 
with MOG35-55 in CFA and at 
days -1, 3, 5 and 9 of 
immunization animals were 
given 150µg of either $-MOG 
mAb (filled symbols) or equal 
concentration/volume of isotype 
control Ab or PBS (open 
symbols) by i.v. injection into 
the tail vein. Mice were 
examined daily for clinical 
disease and the table 
corresponds to the graph 
shown above. The figures are 
representative of at least two 
separate experiments (total 
n#10) and were analyzed for 
statistical significance using a 
Student's t-test (*<0,05, 
#<0,01). 
 
 
 
 
 
 
 
 
Figure 9 !  Mouse and human 
rMOG induce EAE 
independent of classical 
complement mediated Abs 
response. 
wt (circles) and  C1q
-/-
 
(triangles) mice were 
immunized with mouse rMOG1-
121 (open symbols) or human 
rMOG1-125 (filled symbols). Mice 
were examined daily for clinical 
disease and the table 
corresponds to the graph 
shown above. The figures are 
representative of at least two 
separate experiments (total 
n#10) and were analyzed for 
statistical significance using a 
Student's t-test (*<0,05, 
#<0,01). 
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Figure 10 !  Demyelinating 
Abs drive the disease 
process in a complement 
dependent fashion. 
wt (circles) and  C1q
-/-
 
(triangles) mice were 
immunized with MOG35-55 in 
CFA and at days -1, 3, 5 and 9 
of immunization animals were 
given 150µg of either $-MOG 
mAb (filled symbols) or equal 
concentration/volume of isotype 
control Ab or PBS (open 
symbols) by i.v. injection into 
the tail vein. Mice were 
examined daily for clinical 
disease and the table 
corresponds to the graph 
shown above. The figures are 
representative of at least two 
separate experiments (total 
n#10) and were analyzed for 
statistical significance using a 
Student's t-test (*<0,05, 
#<0,01). 
 
 
 
Histopathological analysis revealed that anti-MOG-mAb induced demyelination is 
completely dependent on the activity of complement. Macrophages are visible in 
areas of demyelination and constitute the majority of the infiltrated cells (Figure 12). 
In contrast to FcR!-/- or wt mice, injection of anti-MOG-mAb in C1q-/- mice did not 
affect the degree of demyelination or inflammation (Figure 12). While the 
complement cascade appears to be critical for the demyelination mediated by the 
injection of anti-MOG-mAb, lack of complement per se did not alter the disease 
course evident by comparing untreated MOG-immunized C1q-/- and wt mice (Figure 
10) emphasizing again that MOG-induced EAE in C57BL/6 mice develops completely 
independent of anti-MOG Ab raised by the immunization. 
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Figure 11 !  Histological analysis of CNS 
tissue from FcR!
-/-
, JH
-/-
 and JH
-/-
/FcR!
-/-
 mice.  
Paraffin-embedded spinal cord lateral column 
white matter of lumbar sections were prepared 
from perfused wt, JH
-/-
 , FcR!
-/-
 and JH
-/-
/FcR!
-/- 
animals at day 35 after induction of EAE with 
MOG35-55. Hematoxylin and eosin (H&E) stains 
infiltrated cells, whereas luxol fast blue (LFB) 
shows myelin. Immunocytochemistry for CD3
+
, 
MAC-3
+
 and B220
+
 subsets, shows infiltrated T 
cells, macrophages and B cells respectively. 
Scale bar, 200µm. 
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Figure 12 !  Mouse Histological analysis of CNS tissue from "-MOG mAb treated 
C1q
-/-
 and FcR!
-/-
 mice. 
Spinal cords were isolated 19 dpi from randomly selected and perfused wt, FcR!
-/-
 and 
C1q
-/-
 mice and embedded into paraffin. Representative lumbar sections were analyzed 
for demyelination and cell infiltration. Demyelination is depicted by luxol-fast blue 
staining (LFB), and cellular infiltration by hematoxylin and eosin (H&E). Infiltration of T 
cells (CD3), macrophages/monocytes (MAC-3) and B cells (B220) where also 
compared. Scale bar, 200µm.  
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1. Discussion of the role the role of B cells and Abs in the pathogenesis of 
EAE 
 
Although B cells and plasma cells are known to be associated with MS lesions, 
information on their physiological and pathological function in the brain is still sparse. 
The histological findings suggest a role for B cells in the disease process. B cells and 
plasma cells are numerous in chronic lesions and in areas of active myelin 
breakdown1-8, although it is not clear if CNS invading B cells are not an 
epiphenomenon as a results of antigen spreading. Elevated Ig levels are present in 
the CSF of more than 90% of patients with definite MS7, 9. Despite the apparent 
involvement of B cells in MS, data obtained in the EAE model have been conflicting. 
We wanted to assess their contribution to the disease process of EAE and sought to 
resolve the conflicting information surrounding the role of humoral immunity in EAE.  
 
Here we used an array of different mutant strains and different genetic backgrounds 
and failed to establish any disease promoting function of B cells or Abs in MOG-
peptide induced EAE. In contrast to the results we have obtained in our genetically B 
cell-deficient mouse model, previous studies in rat and murine models that report that 
EAE induction does not occur in B cell-depleted animals10, 11. Our results in MOG 
peptide-immunized BL/6 and JH
-/- mice are in agreement with others showing that 
MBP- or MOG-peptide immunized, B cell-deficient B10.PLµMT (H-2u) and 
C57BL/6µMT (H-2b) develop severe EAE12-16. It has been suggested that B cells, 
while not required for peptide-induced EAE development, are vital for processing and 
presenting full-length protein12, 15, 17, 18.  However, two important differences exist 
between our B cell-deficient mice and those previously used.  
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First of all, the earlier B cell-deficient animals were obtained by depletion of B cells 
with infusion of anti-IgM Abs in neonatal animals10, 11. Later studies suggested that 
anti IgM-treated animals were defective in other aspects of the immune response, 
including T cell activity, making interpretation of the original studies difficult19-21. 
Secondly, the previous studies used µMT mice12-16, 22, 23, which have a disrupted 
membrane µ-heavy chain24. However, µMT mice have been shown to harbor IgA and 
IgA-producing B cells casting doubt upon the applicability of this B-cell deficiency 
model25. Our mice (JH
-/-), which have a targeted deletion of the heavy J gene 
segments, completely lack Ig expression and mature B cells26. Thus model has the 
advantage of eliminating any possibility of B cell leakage or unknown deleterious 
effects on other APC from infusion of exogenous protein.  
 
In agreement with Lyons and colleagues, we demonstrate a requirement for B cells in 
EAE induction and progression depending on the nature of the Ag15. Our data 
suggest that B cells play a central role in the initiation of protein-induced EAE but not 
EAE induced by an encephalitogenic peptide from the same protein and that the lack 
of EAE in the JH
-/- mice was not due to the lack of T cell priming to MOG protein. 
Previous studies have suggested that different APC population are required for 
presenting peptide versus protein Ag to naïve T cells27, 28. DCs are most efficient at 
priming a peptide-induced response, whereas B cells were critical for the priming to 
some protein Ag11, 29, 30. Although in some others studies B cells appeared to be 
generally crucial for T cell priming in vivo27, 31-39 or were able to stimulate T cells in 
vitro40-51, our data exclude the possibility that B cells influence EAE solely through 
antigen presentation for T cell activation27, 52, 53.  
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Our data support the hypothesis that the initiating APCs in a immune responses to 
peptide antigens are most likely DCs. DCs efficiently take up, process, and present 
soluble protein, and can stimulate naïve T cells more efficiently than B cells or 
macrophages43, 54-61. Together, the results described here indicate that MOG protein 
immunized JH
-/- mice could process and present Ag and were primed to the 
encephalitogenic MOG 35-55 epitope in vivo. It is possible that processing and 
presentation of other epitopes present in MOG protein could differ between wt and B 
cell-/- mice, and that these other epitopes may affect disease expression in B cell-/- 
mice. Furthermore, the interaction between T and B cells is thought to play a major 
role in determining to which epitopes generate an immune response i35, 62-65. Perhaps 
B cell-/- mice are incapable of inducing the T cell response, since they fail to present 
the dominant encephalitogenic epitope or to respond to other, uncharacterized EAE-
enhancing epitopes within the MOG protein66. The MOG gene is located within the 
MHC, and low levels of MOG transcription are reported to occur within primary and 
secondary lymphoid organs67-69. This observation raised the possibility that strain 
specific differences in MOG expression outside the CNS could influence the 
composition of the B cell repertoire. An alternative mechanism could be that the 
presence of a conformational mimic of MOG encoded within the MHC could mediate 
a tolerogenic event70. However, in analogy to molecular mimicry in which structural 
and sequence homologies between foreign and self Ags can trigger autoimmunity 
and in some cases tolerance, it is possible that tolerance to one self Ag may be 
induced by cross-reactivity of the B cell receptor with another component of self71-73. 
 
Studies of the anti-MOG antibody repertoire18, 70, 74-76 indirectly suggest that 
recognition  of  conformational  determinants  of  MOG  protein  may  be an important  
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requirement for pathogenicity. Showing that in terms of effector mechanisms, IgG 
deposition and complement activation occur exclusively in association with these 
conformational Abs77. It has been previously been established that the mAb 8-18C5 
binds to discontinuous (i.e. conformation-dependent) determinants but not to linear 
MOG peptides78, 79.   
 
Von Buedingen et al. reporte that Abs raised in marmosets against rat MOG peptides 
could not transfer EAE to MBP primed animals, whereas antisera that include 
antibodies recognizing conformational determinants transferred a severe disease 
with regards to CNS lesions and demyelination77. We however were able to dismiss 
the possibility of a crucial role for autoreactive conformational Abs in trafficking 
encephalitognic T cells into the CNS or a role for Abs immune regulation in MOG 
protein induced EAE. Also, our findings concerning the Ab-independent contribution 
of B cells altering T cell activation and expansion are in concordance with published 
data, which showed that efficient in vivo priming of T cells, to both peptides and 
proteins, occurs in B cell-deficient mice52. It is possible that internalization of Ag 
through the BCR could generate a different set of epitopes that are presented to T 
cells27, 80-82, thereby activating a unique subset of Ag-specific T cells. Studies of auto-
Ag have shown that B cells elicited with foreign cross-reactivity Ag can present self-
peptides, resulting in priming of autoreactive T cells66, 83.  
 
Mice genetically deficient in mature B cells and immunized with MBP resulted in 
induction of EAE with impaired recovery when compared to wt mice12. B cell-deficient 
mice failed to recover from acute EAE, suggesting a role for B cells in immune 
regulation.  In  addition, recent  studies  indicate  that  regulatory  B  cells  develop  in  
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several murine models of chronic inflammation, including rheumatoid arthritis84, 85, 
lupus86, bowel disease87-89, autoimmune diabetes90 and EAE12, 14, 91, 92. Fillatreau et 
al. demonstrate that recovery from EAE was dependent on the presence of 
autoantigen-reactive B cells14. The regulatory function may be directly accomplished 
by the production of regulatory cytokines IL-10 and TGF-! or by the ability of B cells 
to interact with pathogenic T cells to dampen harmful immune responses93. In EAE, 
both B cells and regulatory T cells are involved in the regulation of CNS autoimmune 
disease; B cells may limit the continued expansion of fresh pathogenic T cells from 
lymph nodes, whereas regulatory T cells directly control the disease at the site of 
inflammation94 or they suppress inflammation by restoring the Th1/Th2 balance14 
through skewing of Th cells to a Th2 response. An absence of Th2 cytokines may 
allow continued expansion and migration of activated Th1 encephalitogenic cells into 
the CNS, thus prolonging inflammation and demyelination in the target organs. 
Activation of T cells also needs an “unspecific” costimultory support in addition to the 
“specific” TCR-mediated signal between APC and T cell. B cell may be an important 
cellular factor in supporting T cell activation in the immune periphery and the CNS.  
 
2. Discussion of the contribution of FcR and complement to EAE 
 
Ab-mediated tissue damage is widely held to be mediated primarily through the 
action of immune complexes (IC), complement- and FcR activation. The FcR! chain 
is in this context not only important for cell activation but also necessary for the 
efficient assembly and cell-surface expression of these four types of FcRs, including 
FcRI, Fc!RIII, Fc"RI and Fc#RI. Therefore, FcR! deletion results in the combined 
deficiency of activating type FcRs95.  FcRs  have been implicated in the pathogenesis  
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of EAE due to the fact that FcR!-/- mice are relatively EAE-resistant even though they 
develope comparable levels of MOG-specific Abs96, 97. Our findings are in agreement 
with earlier studies, which also reported drastically attenuated EAE in FcR!-/- on a 
DBA/1 and B6-129-background22, 96-98.  
 
Several independent studies support the notion that CNS-resident cells, in particular 
microglia, recognize IC and Ab-deposits within the CNS leading to phagocytosis of 
opsonized target cells99. However, deletion of FcR! from the CNS-parenchyma did 
not impact on EAE susceptibility, clinical disease or demyelination, whereas the 
absence of FcR! in the peripheral immune compartment conveys protection. 
Accordingly, the resistance of FcR!-/- mice to developing EAE is not due to the 
inability of CNS-resident cells to recognize and become activated by Abs or ICs. 
 
A vital role for Ig-binding FcRs is in apparent conflict with our failure to establish any 
pathogenic function of B cells in EAE: To resolve this paradox, we demonstrated that 
the deficiency in FcR! lesions immunity independently of B cells or Igs and that the 
EAE-resistance of FcR!-/- mice cannot be attributed to humoral immunity. The notion 
that FcR! functions independent of FcR mediated Ab-recognition is supported by the 
recent report by Szalai et al., which demonstrates that the Ab-binding FcR# units are 
not required to develop EAE100. FcR! is not only critical for FcR-mediated signaling, 
but has also been shown to be involved in the signal transduction of several other 
FcR-unrelated receptor complexes on different cell types: NKR-P1 on NK-, NK T- 
and dendritic-cells (DCs); #$-TCR on T cells; Pir-A on DCs, macrophages and B 
cells and GPIb on platelets.  Furthermore FcR! is closely related to the %-chain of the  
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T cell antigen receptor (TCR)/CD3 complex and in fact FcR!-% heterodimers and 
FcR!-FcR! homodimers can participate in TCR formation and function100-105. Szalai 
et al. suggested that FcR! signaling in !/& T cells could explain the EAE resistance of 
FcR!-/- mice100.  
 
They implied that expression of FcR! by !& T cells, probably in conjunction with the T 
cell receptor/CD3 complex, is potentially required for full development of EAE100. Our 
data however, dismiss any vital FcR! function in B or T lymphocytes and point 
towards a crucial role of FcR! in the accessory cell compartment. Reconstitution of 
FcR!-deficient mice with wt accessory cells renders them fully EAE susceptible, even 
when lymphocytes remain FcR!-deficient. We suspected that the loss of FcR! 
impairs APC capacity and thus the expansion of encephalitogenic T cells. However, 
our data dismiss the involvement of FcR! in APC function or T cell expansion. In this 
context, we found that FcR! does not affect the induction of DC maturation, Ag-
processing or presentation. In support of these findings, FcR!-/- mice do not develop 
EAE even when an expanded population of fully primed encephalitogenic 
lymphocytes is adoptively transferred, again underlining that FcR!-mediated 
accessory cell activation is required for the effector phase of EAE.  
 
Murine models of autoimmune disease indicate the indispensable roles of the 
inhibitory FcRs in the suppression of such disorders, whereas activating-type FcRs 
are crucial for the onset and exacerbation of the disease. The development of many 
autoimmune diseases may be caused by impairment of the Fc receptor regulatory 
system95.   It  is  feasible  that  the  EAE  resistance   of  FcR!-/-   mice  is  caused  by  
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unbalanced steady state signal transduction, skewing the response towards 
attenuated status. This notion is supported by studies with mice lacking another 
ITAM-bearing adapter molecule, namely DAP-12, which were also resistant to MOG-
peptide induced EAE106.  
 
Active immunization with either MOG-protein or peptide leads to the production of 
#MOG specific Igs in vivo. While we cannot demonstrate any pathogenic function of 
these Abs, inoculation with specific #MOG Abs in vivo drastically exacerbates clinical 
disease and demyelination. Also, Litzenburger et al. found that transgenic mice 
expressing a B cell receptor specific for MOG, while not developing spontaneous 
disease, develop exacerbated EAE after immunization79. In line with the idea that the 
impact of the FcR! in EAE is B cell and Ab-independent, FcR! deficient mice are 
rendered susceptible to EAE when inoculated with demyelinating #MOG Abs. 
Interestingly, while succumbing to clinical EAE after #MOG Ab injection, FcR!-/- mice 
still displayed a significant delay in disease onset supporting that the FcR! function in 
EAE is unrelated to Abs. The fact that complement-deficient mice are fully EAE 
susceptible again supports the notion that humoral immunity is not relevant for EAE 
development induced by active immunization. However we demonstrate that large 
amounts of inoculated pathogenic Abs mediate their disease promoting function 
exclusively via the complement cascade. The role of complement activation in EAE 
has been debated107-109. Loss of C3 attenuates EAE110 and expression of the 
complement inhibitor sCrry prevents EAE111. Also, complement activation appears to 
be crucial in the context of EAE exacerbated by the inoculation of demyelinating 
Abs112-115. On the other hand, Boos et al.108 and Calida et al.109 could demonstrate 
that  key  components  of  the  complement  system,  such  as  C3  and  C4,  are  not  
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involved in MOG35-55 induced EAE pathogenesis. We found that complement 
activation mediated by C1q is crucial for the demyelinating effects of #-MOG-Abs, yet 
that loss of this pathway does not impact on disease development in the absence of 
inoculated demyelinating Abs. 
 
Taken together, our findings help explaining the discrepancies and controversial 
findings with regards to humoral immunity in EAE. In MS, enhanced titers of anti-
myelin antibodies in serum and CSF have been described in MS patients and in a 
subgroup of patients with clinical isolated syndrome the levels of anti-MOG Abs have 
been suggested to be useful as a prognostic marker3. In EAE, we did not observe 
any correlation between Ab-titers and EAE severity. In fact, it is feasible that the B 
cell activity and the intrathecal presence of B cells serve a regulatory attenuating 
function in MS14, 92, 93. The presence of Ig and complement deposits suggests that 
anti-myelin Abs are involved in the demyelinating process. The fact that 
administration of #MOG Abs exacerbates EAE is in agreement with the conclusions 
drawn from the histopathological analysis of MS tissue. In particular, Lucchinetti and 
coworkers identified a subtype of MS pathology in which elevated levels of Ab, 
complement and plasma cells can be observed in situ2, 116. Modeling this pathology, 
administered #Myelin Abs can clearly exacerbate demyelination and clinical disease. 
However, a pathogenic function of host-derived Abs raised by the active 
immunization cannot be established in the standard models of EAE. 
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1. Mice  
C57BL/6-CD45.1 and congenic C57BL/6-CD45.2 mice were obtained from Harlan 
Laboratories (Netherlands), FcR"-/- and JH
-/- mice from Taconic (Germantown, NY). 
MOG-specific TCR transgenic (Tg) C57BL/6 (2D2) mice were provided by V.J. 
Kuchroo1 (Harvard Medical School, Boston, MA). C1q-/- mice2  were obtained from A. 
Aguzzi (University Hospital, Zurich) and the SMARTA p11 TCR-Tg and Rag1-/- were 
provided by R. Zinkernagel (University Hospital, Zurich)3. µMT mice were kindly 
provided by Dr. Charles A. Janeway Jr. All mice were bred at the animal facilities of 
the University of Zurich under specific pathogen-free conditions. Animal experiments 
and breeding were approved by the Swiss Veterinary Office (#69/2003, #70/2003 
and #13/2006). 
 
2. Reagents 
Murine His6-tagged recombinant mouse (amino acids 1-121)
4 and human (amino 
acids 1-125) MOG5 was expressed in E.coli and purified using metal chelate 
chromatograph. MOG35-55-peptide (MEVGWYRSPFSR VVHLYRNGK) and SMARTA 
(LCMV) p11 (GPDIYKGVYQFKSVEFD) were synthesized by GenScript, 
(Piscataway, NJ). Keyhole limpet hemocyanin (KLH) was purchased from Fluka 
(Buchs, CH), Concanavalin A and LPS were bought from Sigma (Switzerland), 
mouse monoclonal anti-MOG antibody 8-18C5 (IgG1)
6 was provided by Prof. N. 
Goebels (University Hospital, Zurich). 
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3. Bone marrow chimeric mice  
Irradiation Bone-marrow (BM) chimeric mice were generated as described 
previously7. BM donor mice were killed using CO2 and BM cells were isolated
 by 
flushing femur, tibia and hip bones with PBS. Bone marrow cells were then passed 
through a cell strainer with pore size of 100µm and cells were washed with PBS. 
Recipient mice were lethally irradiated with 1100 rads (split dose) and were 
intravenously injected with 20x106 donor BM cells. Engraftment took place over 8 
weeks of recovery, before the mice were used in EAE experiments. 
 
4. Induction of EAE and clinical assessment 
EAE was induced by s.c. flank injection of 200µg of MOG35-55-peptide or rMOG-
protein emulsified (1:1) in Complete Freund’s Adjuvant (CFA) (Difco, Detroit, MI) on 
day 0, supplemented by i.p. injections of 200ng of pertussis toxin (PT) (Sigma) on 
day 0 and 2.  
 
For adoptive transfer studies, donor mice were immunized as described above. 11 
days later the mice were sacrificed, spleen and LNs were removed, homogenized 
and red blood cells lysed. For lysis of red blood cells, spleenocytes were incubated 
on ice for 10 minutes in lysing buffer (containg NH4CL, KHCO3 and EDTA). Cells 
were filtered through a 100µm cell strainer and were subsequently cultured for 4 days 
in RPMI 1640 supplemented with 10% FCS and 1% penicillin/streptomycin and in the 
presence of 50µg/ml MOG peptide and 2,5ng/ml IL-12 at a concentration of 4x106 
cells/ml. MOG35-55-reactive lymphocytes were then washed and injected into recipient 
mice (20-30 x 106 cells/mouse). Animals also received 200ng/mouse PT several 
hours later and on day 2 post-cell transfer.  
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The mice were evaluated daily for clinical signs of disease on a scale of 0-5 with 
gradations of 0.25 for intermediate scores: 0, no clinical signs; 1, loss of tail tone; 2, 
limp tail and hind limb weakness (waddling gait); 3, hind limb paralysis; 4, hind and 
fore limb paralysis (score > 4 to be sacrificed); 5, death. Each time point shown is the 
average disease score of each group. Statistical significance was assessed using an 
unpaired Student t-Test.  
 
5. LT!R-Fc treatment  
C57BL/6 mice were injected i.p. with 100 µg of human LT!R-Fc Fusion protein 
(generously provided by Dr. Yang Xin Fu, University of Chicago) or 100 µg human 
IgG control (Bioexpress) 7 days prior to immunization with MOG and weekly 
thereafter.  
 
6. Generation of bone marrow-derived DCs 
Femurs from bone marrow donor mice were removed and bone marrow cells were 
isolated by flushing of the bones with PBS; cells were then filtered through a cell 
strainer with a pore size of 100 µm. Cells (2x105 cells/ml) were cultured in RPMI 
medium containing 10% FCS with the addition of 10% conditioned medium obtained 
from X-63 cells transfected with a plasmid containing granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (obtained from A. Rolink, University of Basel, 
Switzerland). After at least 6 days, bone marrow–derived DCs were matured with 10 
µg/ml of lipopolysaccharide overnight; immature bone marrow–derived DCs were 
maintained in medium containing GM-CSF. Bone marrow–derived DCs were used 
from day 7 to day 9. 
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7. T cell expansion assays 
Mice were immunized by flank injections of CFA alone, MOG35-55/CFA or MOG1-
121/CFA. After 7 days, the axillary and inguinal lymph nodes (LN) as well as spleens 
were removed and homogenized. 2x105 cells were seeded as triplicates in a 96 well 
plate and pulsed with 0.5, 5 and 50µg/ml MOG or 5µg/ml concanavalin-A (Fluka, 
Buchs CH). After 24 hours, 1µCi 3[H] thymidine (Fluka, Buchs CH) was added and 
incubated for an additional 24 hours before cells were harvested using a Filtermate 
harvester (Inotech, Dottikon CH) and thymidine incorporation was assessed and 
Wallac MicroBeta® TriLux- scintillation-counter (PerkinElmer). For cytokine analysis, 
sister cultures were harvested 48 hours after culture and supernatants were analysed 
by ELISA for IFN-" and IL-2 (BD PharMingen). 
 
For in vitro proliferation of transgenic T cells, spleens were collected from naive 
transgenic mice and CD4+ T cells were purified with BD-IMag magnetic beads (BD 
Pharmingen). The purity of T cell isolation was verified by flow cytometry. The 
transgenic T cells (1x105) were cultured in a 96-well plate together with immature or 
mature bone marrow DCs. Before coculture, bone marrow DCs were pulsed for 3h 
with 1 mg/ml of Tg TCR specific peptide in RPMI medium, then were washed and 
were irradiated with 2,000 rads. Unpulsed DCs were used as a control, as were T 
cells cultured alone. Cells were incubated for 2 days and [3H]thymidine was added 
for the last 18 h of culture. 
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For in vivo proliferation assays, mice were immunized with 200 µg MOG35-55, rMOG1-
121 emulsified in CFA or CFA alone. Several hours later, the mice were injected i.v. 
with CFSE (carbofluorescein diacetate succinimidyl ester)-labeled splenocytes 
(10µM) (Invitrogen - Moleculare Probes) obtained from TcR Tg mice. 4 days later, 
spleens and LNs are isolated from immunized mice and proliferation of transgenic 
CD4 T cells was performed by FACS analysis using specific antibodies to TCR V#3.2 
and V!1.1. 
 
8. Enzyme-linked immunosorbent assay (ELISA)  
The culture supernatants (described above) were analyzed using commercially 
available murine ELISA-kits for IFN-" and IL-2 (BD Biosciences Mountain View, CA), 
according to the manufacturer`s instructions. For determining Ig-isotype ELISA plates 
were coated with 10µg mouse rMOG1-121 in 0.1 M NaHCO3 (pH 9.6) over night (o.N.) 
at 4°C and blocked with 1% (w/v) bovine serum albumin (BSA). Serial dilutions of 
serum in PBS were added to Ag-coated wells and incubated o.N. at 4°C. After 
washing, affinity-purified peroxidase-conjugated goat Abs to mouse Igs, IgG or IgM 
(Sigma, St. Louis, MO) were added, at a dilution of 1:1000 in PBS. Binding was 
revealed using stabilized chromogen (Biosource, Belgium) and the absorbance at 
450nm was read on an micro plate reader (Bio-Rad, CA USA). 
 
9. Enzyme Linked Immuno Spot Technique (ELISpot) 
For ELISpot assays, lymphocytes were isolated from LNs and spleen of MOG35-55- 
and MOG1-121-immunized mice on day 7 dpi, as described above. Cells (2 x 10
5) 
were plated per well in complete  RPMI medium  containing 50 µg/ml  MOG35-55 in 
96-well  plates  (Millipore)  coated  with 7.5  µg/ml  anti-IFN-"  (AN18; Mabtech)  or  2  
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µg/ml anti-IL-17 (TC11-18H10; BD Pharmingen) Abs. The plates were incubated at 
37°C, 5% CO2 for 18 (anti-IL-17) or 20 (anti-IFN-") hours at which point cells were 
discarded and plates were washed with PBS. Then, 0.5 µg/ml of biotin-conjugated 
anti-IFN-" (R4-6A2; Mabtech) or 1 µg/ml of biotin-conjugated anti-IL-17 (TC11-8H4.1; 
BD Pharmingen) detection Abs was added and incubated at 25°C for 2h and 4 h, 
respectively. After plates were washed, streptavidin-alkaline phosphatase (Mabtech) 
was added, followed by incubation for 1 h at 25°C. Plates were washed with PBS and 
75 µl of the substrate solution BCIP/NBT-plus (5-bromo-4-chloro-3-indolylphosphate-
nitro blue tetrazolium) was added to the wells, which were developed until distinct 
spots emerged. Plates were analysed with an enzyme-linked immunospot reader 
(Immunospot; CTL). 
 
10. Histology  
Mice were transcardially perfused with 20ml PBS and subsequent with 4% 
(weight/volume) paraformaldehyde in PBS. Spinal columns were removed and were 
fixed in 4% (weight/volume) paraformaldehyde in PBS. Spinal cords were then 
dissected and were embedded in paraffin before being stained with either 
hematoxylin and eosin or with anti-CD3, anti-B220 or anti-Mac-3 antibodies (BD 
Pharmingen and Serotec) to assess infiltration of inflammatory cells. Luxol fast blue 
stain was used to determine the degree of demyelination . 
 
11. Flow cytometry  
For Flowcytofluorometric analysis we used the following Abs diluted in FACS buffer 
(PBS  supplemented  with  FCS  and  sodium  azide):  anti-CD45  (30/F11), anti-CD4  
(RM4-5),  anti-V"3.2  (RR3-16),  anti-CD11b (M1/70), anti-CD11c(GS-32), anti-GR-1  
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(RB6-8C5) and anti-B220 (RA3-6B2), anti-CD40 (3/23), anti-CD62L (Mel-14), anti-
CD162 (2Ph1), anti-VLA-4 (R1-2), anti-CD5 (53-7.3), anti-CD25 (PC61), anti-Ly5.1 
(104), anti-Ly5.2 (A20). All antibodies were purchased from BD Pharmingen. For 
analysis of CNS invading cells, mice were euthanised with CO2 and perfused 
intracardially with PBS. Spinal cord was flushed out with PBS and the brain was 
dissected to isolate the brainstem. Tissues were digested using liberase treatment 
(400 µg/ml liberase (Roche) and 200 µg/ml DNase (Roche)) at 37°C for 30 min. The 
tissues were then homogenised and strained through a 100µm nylon filter (Fisher). 
After centrifugation, cell suspensions were resuspended in 30% Percoll (Pharmacia) 
and centrifuged at 18,500g for 30 min at 4°C. Interphase cells were collected and 
washed extensively before being staining. For flow cytometry, we incubated the 
primary antibody for 20 min at 4°C. Cells were then washed with FACS buffer and 
centrifuged for 2 min at room temperature (RT) prior to staining for 15 min with the 
secondary antibody at 4°C. Cells were washed, centrifuged and resuspended in 300 
µl facs buffer for subsequent analysis. We analysed the cells using a FACS-Canto 
(BD Pharmingen) with Cell-DivaTM software. Post-acquisition analysis was performed 
using FLOWJOTM software. 
 
12. Protein purification  
The expression of recombinant MOG was performed in transformed E. coli bacteria 
of the DH5" strain. The expression vector introduced  contains an IPTG inducible 
promoter, the cDNA coding for the extracellular domain of mouse and human MOG 
and a histidine tag sequence coding for 6 histidines, to allow purification by nickel-
chelate chromatography. 600ml of selective culture medium was inoculated with an 
transformed  E. coli glycerol  stock and incubated  overnight at  37°C. For 30 minutes  
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the bacterial pellet was then resuspended in 6 x 1 liter of selective culture medium 
(LB medium, 50 µg/ml ampicillin) and shaken at 37°C. IPTG (BioTech Trade) were 
added per liter of culture to induce MOG expression. Incubation was continued for a 
further 3-4 hours, bacteria were centrifuged (20min, 5000rpm, 4°C) resuspended in 
200ml PBS and centrifuged again. The pellet was stored overnight at -20°C. The 
pooled bacterial pellet was resuspended in 40ml PBS and sonicated for 10 minutes 
on ice (Bioblock Scientific, France) to lyse the cells. Recombinant MOG is insoluble 
in PBS and forms inclusion bodies. After centrifugation (120min, 12000rpm, 4°C) 
containing the MOG inclusion bodies and other insoluble proteins was resuspended 
in urea buffer (6M urea; 0.5M NaCl; 0.1M KH2PO4; pH 8) and sonicated for 10 
minutes to dissolve the inclusion bodies. The suspension was again centrifuged and 
the supernatant containing the dissolved MOG was used for affinity chromatography.  
 
The affinity column (HiTrap Chelating HP 5ml, Amersham) was washed sequentially 
with dH2O and with 1% EDTA/0.05% Tween20 to remove the 70% ethanol used for 
storage and any remaining nickel. The column was loaded with a 1% nickel (Ni 2+) 
solution, washed with dH2O and equilibrated with urea buffer. The sample was 
loaded on to the column, and the flow rate was set  (1ml/min). The column washed 
with 50ml wash buffer (40 mM imidazole in urea buffer). The elution was performed 
with an linear imidazole gradient with 50ml elution buffer (500 mM imidazole in urea 
buffer). Fractions of 2ml were collected and analysed by SDS-PAGE. The protein 
concentration in the eluate was monitored by photometer at 280nm. After SDS-PAGE 
analysis the protein-containing eluate fractions were pooled and placed in a dialysis 
cassette (Pierce, Switzerland) in 5 liters PBS. Dialysis was performed twice overnight 
at 4°C against PBs and the MOG preparation was verified by SDS-PAGE.  
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13. SDS-Page  
SDS-Page was carried out according to the method described by Laemmli8 using 
12% polyacrylamide gels. Transfer of protein from gel to blots was done using the 
wet method. Nitrocellulose membranes, stacking filter paper and resolved gel were 
soaked in transfer buffer and stacked on top of each other such that membrane, gel 
and filters were aligned exactly on top of each with gel on cathode side and the 
electrical leads connected to a power supply. A current of 0.65mA/cm2 gel was 
applied for a period of 1 hour. To reveal separated proteins on the nitrocellulose 
membrane, membrane was stained with 0,2% Ponceau-staining solution (Biorad, 
Germany) for 10 min and  destained with dH2O. After blotting, membranes were 
blocked for 1 hour at room temperature in blocking buffer (1% FCS in PBS). 
Membranes were incubated with unlabeled specific primary monoclonal antibody 
over night at 4°C. Following a series of washing steps, membranes were incubated 
for 1h with a secondary antibody coupled to horse radish peroxidase. Specific bands 
were detected using the ECL-pico system (Pierce, Switzerland). The membranes 
were exposed to film in the dark for a time period, ranging from a few seconds to 1h 
and developed using a Kodak X-OMAT film-developing machine.  
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Autoantibody-mediated demyelination depends on complement activation but not 
activatory Fc receptors  Proc.Natl. Acad. Sci. USA 103, 18697-18702 (2006) 
 
The precise mechanisms leading to CNS inflammation and myelin destruction in both Multiple 
Sclerosis (MS) as well as Experimental Autoimmune Encephalomyelitis (EAE) remain subject of 
intense debate. In both MS and EAE, auto-antibodies (Abs) are thought to be involved in tissue 
destruction through recruiting Fc receptor (FcR)-bearing cells or direct cytotoxic effects through 
the activation of the complement pathway. While intrathecal immunoglobulin (Ig) production and 
Ig-deposition in inflammatory lesions is a hallmark of MS, mice deficient in B cells and Igs 
develop severe EAE. Paradoxically, mice of the same genetic background, but deficient in 
FcR!, are EAE-resistant. We found that the functional expression of FcR! on systemic 
accessory cells, but not CNS-resident cells, appears to be vital for the development of CNS-
inflammation, independent of antigen presenting cell (APC)-function or antibody involvement. 
On the other hand, we found that the injection of anti-myelin oligodendrocyte glycoprotein 
(MOG)-Abs drastically worsens disease severity, inflammation and demyelination. Using FcR!-/- 
as well as C1q-/- mice we could definitively establish that the demyelinating capacity of such 
auto-Abs in vivo relies entirely on complement activation and is FcR-independent.  
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I. Gutcher, E. Urich, K. Wolter, M. Prinz and B. Becher 
Interleukin 18-independent engagement of interleukin 18 receptor-! is required for 
autoimmune inflammation                         Nature Immunology 7, 946-953 (2006) 
 
T helper type 1 (TH1) lymphocytes are considered to be the main pathogenic cell type 
responsible for organ-specific autoimmune inflammation. As interleukin 18 (IL-18) is a cofactor 
with IL-12 in promoting TH1 cell development, we examined the function of IL-18 and its 
receptor, IL-18R, in autoimmune central nervous system inflammation. Similar to IL-12-deficient 
mice, IL-18-deficient mice were susceptible to experimental autoimmune encephalomyelitis. In 
contrast, IL-18R!-deficient mice were resistant to experimental autoimmune encephalomyelitis, 
indicating involvement of an IL-18R! ligand other than IL-18 with encephalitogenic properties. 
Moreover, engagement of IL-18R! on antigen presenting cells was required for the generation 
of pathogenic IL-17-producing T helper cells. Thus, IL-18 and TH1 cells are dispensable, 
whereas IL-18R! and IL-17-producing T helper cells are required, for autoimmune central 
nervous system inflammation. 
 
 
 
M. Polymenidou, F. Heppner, C. Pellicioli, E. Urich, G. Miele, B. Becher and A. Aguzzi 
Humoral immune response to native eukaryotic prion protein correlates with anti-prion 
protection               Proc. Nat. Acad. Sci. USA 101, 14670-14676 (2004) 
  
Prion diseases are characterized by the deposition of an abnormal form (termed PrPSc) of the 
cellular prion protein (PrPC). Because antibodies to PrPC can antagonize deposition of PrPSc 
in cultured cells and mice, they may be useful for anti-prion therapy. However, induction of 
protective anti-prion immune responses in WTanimals may be hindered by host tolerance. Here, 
we studied the cellular and molecular basis of tolerance to PrPC. Immunization of Prnpo/o mice 
with bacterially expressed PrP (PrPREC) resulted in vigorous humoral immune responses to 
PrPREC and native cell-surface PrPC. Instead, WT mice yielded antibodies that failed to 
recognize native PrPC despite immunoreactivity with PrPREC, even after immunization with 
PrP-PrP polyprotein and or upon administration of anti- OX40 antibodies. Consequently, 
immunized WT mice experienced insignificantly delayed prion pathogenesis upon peripheral 
prion challenge. Anti-PrP immune responses in Prnpo/o mice were completely abrogated by 
transgenic expression of PrPC in B cells, T cells, neurons, or hepatocytes, but only moderately 
reduced by expression in myelinating cells, despite additional thymic Prnp transcription in each 
case. We conclude that tolerance to PrPC can coexist with immunoreactivity to PrPREC and 
does not depend on thymic PrPC expression. Its circumvention might represent an important 
step toward the development of effective anti-prion immunotherapy. 
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S. Kuenzle, H.C. von Buedingen, M. Meier, M.D. Harrer, E. Urich, B. Becher and N. Goebels 
Pathogen specificity and autoimmunity are distinct features of antigen driven immune 
response in neuroborreliosis                                      (submitted)  
 
Neuroborreliosis (NB) is a chronic infectious disease of the central nervous system caused by a 
tick borne spirochaete, Borrelia burgdorferii (Bb). In addition to direct effects of the causative 
agent, additional immune mediated mechanisms are thought to play a role in the central 
nervous system (CNS) pathology of NB. In order to further understand the involvement of 
humoral immune mechanisms in NB, we dissected the intrathecal antibody responses down to 
the single plasma cell level. Starting with single cell RT-PCR of FACS sorted cerebrospinal fluid 
(CSF) plasma cells from a NB patient, we identified expanded clones and resurrected the 
antigen specificity of their secreted antibodies through recombinant expression of the correctly 
paired Ig heavy and light chain genes as monoclonal antibodies. As expected, we found 
specificity for the causative infectious agent Bb among the clonally expanded plasma cell 
(cePC) derived monoclonal antibodies. However, from an independent cePC of the same 
patient, we could derive mAbs specific for human CNS myelin, without detectable crossreactivity 
with Bb antigens. While reactivity against Bb is an known feature of humoral immune responses 
in NB, we are the first to show a) that immune responses specific for self antigens are a distinct 
feature of CNS infections independent of pathogen reactivity and b) that humoral autoimmunity 
in NB – since found in clonally expanded plasma cells - is the result of a truly antigen driven 
immune response. Our findings indicate, that in NB mechanisms are at play that induce distinct 
immune responses specific for pathogen and self antigens independent from molecular mimicry. 
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